Jetrea

RSS

ocriplasmin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Jetrea. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Jetrea.

For practical information about using Jetrea, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 16/01/2021

Authorisation details

Product details
Name
Jetrea
Agency product number
EMEA/H/C/002381
Active substance
ocriplasmin
International non-proprietary name (INN) or common name
ocriplasmin
Therapeutic area (MeSH)
Retinal Diseases
Anatomical therapeutic chemical (ATC) code
S01XA22
Publication details
Marketing-authorisation holder
Inceptua AB
Revision
15
Date of issue of marketing authorisation valid throughout the European Union
13/03/2013
Contact address

Gustavslundsv. 143
16751 Bromma
Sweden

Product information

11/12/2020 Jetrea - EMEA/H/C/002381 - IA/0053

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

Assessment history

Related content

How useful was this page?

Add your rating